These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23427107)

  • 21. Expression and characterization of a glycine-binding fragment of the N-methyl-D-aspartate receptor subunit NR1.
    Miyazaki J; Nakanishi S; Jingami H
    Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):687-92. PubMed ID: 10359652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycine binding primes NMDA receptor internalization.
    Nong Y; Huang YQ; Ju W; Kalia LV; Ahmadian G; Wang YT; Salter MW
    Nature; 2003 Mar; 422(6929):302-7. PubMed ID: 12646920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia.
    Tsai CH; Huang HC; Liu BL; Li CI; Lu MK; Chen X; Tsai MC; Yang YW; Lane HY
    Psychiatry Clin Neurosci; 2014 Sep; 68(9):692-700. PubMed ID: 24612097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on N-methyl-D-aspartate receptors.
    Kleckner NW; Dingledine R
    Mol Pharmacol; 1989 Sep; 36(3):430-6. PubMed ID: 2550776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycine modulators in schizophrenia.
    Javitt DC
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the glycine site of the N-methyl-D-aspartate receptor in synaptic plasticity induced by pairing.
    Krasteniakov NV; Martina M; Bergeron R
    Eur J Neurosci; 2005 May; 21(10):2782-92. PubMed ID: 15926925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. D-Serine differently modulates NMDA receptor function in rat CA1 hippocampal pyramidal cells and interneurons.
    Martina M; Krasteniakov NV; Bergeron R
    J Physiol; 2003 Apr; 548(Pt 2):411-23. PubMed ID: 12611916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials.
    Pawlak CR; Chen FS; Wu FY; Ho YJ
    Kaohsiung J Med Sci; 2012 Aug; 28(8):407-17. PubMed ID: 22892161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of group I metabotropic glutamate receptors in schizophrenia.
    Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
    Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Divalent cations modulate N-methyl-D-aspartate receptor function at the glycine site.
    Hashemzadeh-Gargari H; Guilarte TR
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1356-62. PubMed ID: 10454514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.
    Kalia LV; Brotchie JM; Fox SH
    Mov Disord; 2013 Feb; 28(2):131-44. PubMed ID: 23225267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
    Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
    Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS; Hammonds MD; Kee BS
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D-cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slices.
    Rouaud E; Billard JM
    Br J Pharmacol; 2003 Nov; 140(6):1051-6. PubMed ID: 14530208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits.
    Chatterton JE; Awobuluyi M; Premkumar LS; Takahashi H; Talantova M; Shin Y; Cui J; Tu S; Sevarino KA; Nakanishi N; Tong G; Lipton SA; Zhang D
    Nature; 2002 Feb; 415(6873):793-8. PubMed ID: 11823786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels.
    Martina M; Gorfinkel Y; Halman S; Lowe JA; Periyalwar P; Schmidt CJ; Bergeron R
    J Physiol; 2004 Jun; 557(Pt 2):489-500. PubMed ID: 15064326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Taurine potentiates presynaptic NMDA receptors in hippocampal Schaffer collateral axons.
    Suárez LM; Solís JM
    Eur J Neurosci; 2006 Jul; 24(2):405-18. PubMed ID: 16836643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.